Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
Bio Pharma Dive
DECEMBER 11, 2024
Wed.Dec 11, 2024
111 
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia
Pharmaceutical Technology
DECEMBER 11, 2024
Er-Kim has extended its exclusive agreement with Ascendis Pharma for endocrinology treatments across multiple countries in Eurasia.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
December 11, 2024: Home Blood Pressure Telemonitoring in Black and Hispanic Patients With Stroke, in This Week’s PCT Grand Rounds
Rethinking Clinical Trials
DECEMBER 11, 2024
Dr. Gbenga Ogedegbe In this Friday’s PCT Grand Rounds, Gbenga Ogedegbe of the NYU Grossman School of Medicine will present “Home Blood Pressure Telemonitoring and Nurse Case Management in Black and Hispanic Patients With Stroke: A Randomized Clinical Trial.” The Grand Rounds session will be held on Friday, December 13, 2024, at 1:00 pm eastern.
ASH 2024 discussions shine spotlight on advances in haemophilia treatments
Pharmaceutical Technology
DECEMBER 11, 2024
When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
With new data, Lilly sets pace for next wave of breast cancer drugs
Bio Pharma Dive
DECEMBER 11, 2024
Vifor Pharma offers £23m to NHS to resolve CMA investigation
Pharmaceutical Technology
DECEMBER 11, 2024
If accepted, Vifor Pharma's 23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Relation-GSK to drive fibrotic and osteoarthritis developments
Pharmaceutical Technology
DECEMBER 11, 2024
Relation has announced two strategic collaborations with GSK, focusing on new therapeutics for fibrotic and osteoarthritis.
GLP-1 drug compounding is in limbo. Will the FDA draw out its decision?
Bio Pharma Dive
DECEMBER 11, 2024
ASH 2024: J&J’s Tecvayli shows promise in transplant-eligible NDMM patient
Pharmaceutical Technology
DECEMBER 11, 2024
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnsons (J&J) Darzalex in combination with chemotherapy.
Lilly’s £279m bet aims to boost UK life sciences sector
Pharmaceutical Technology
DECEMBER 11, 2024
Lillys investment and the UK governments strategic support for life sciences and healthcare represent a pivotal moment for the industry.
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Pharma Times
DECEMBER 11, 2024
Promising results set stage for European marketing authorization
Better prevention and treatment options needed for genital herpes, WHO says
Pharmaceutical Technology
DECEMBER 11, 2024
Updated figures from the WHO show that more than one in five adults aged between 15 and 49 globally have the infection.
iOnctura achieves new clinical milestones in uveal melanoma therapy
Pharma Times
DECEMBER 11, 2024
Successful phase 1 study highlights potential of roginolisib
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Dr Myles Greenberg becomes president and CEO of InCarda Therapeutics
Pharmaceutical Technology
DECEMBER 11, 2024
InCarda Therapeutics has announced the appointment of Dr Myles Greenberg as its new president and chief executive officer (CEO).
How Pfizer management outplayed activist investor Starboard
Pharmaceutical Technology
DECEMBER 11, 2024
The push to replace Albert Bourla as Pfizers CEO drew attention from the pharma industry but was soon derailed by several events.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Overcoming the first hurdles: Navigating early phase challenges for biotechs
Pharmaceutical Technology
DECEMBER 11, 2024
Appropriately planning and conducting early phase clinical trials is critical to setting the stage for successful pivotal studies.
The Innovations Shoring Up Clinical Supply Chain Integrity in the Age of Advanced Therapies
Pharmaceutical Technology
DECEMBER 11, 2024
Missing and incomplete data can cause headaches for clinical trial operators; new innovations are providing an antidote.
Opening the Gates to New Study Coordinator Talent and Workforce Mindsets
ACRP blog
DECEMBER 11, 2024
Youve probably heard it all before: The clinical research enterprise has a problem with expecting new hires in what are often basically low-paying, entry-level positions to already have two or more years of experience with the positions duties. Its a talent acquisition model that does no one any favors, especially at the study site level where a healthy pipeline of new clinical research coordinators (CRCs) would go a long way to alleviating delays in trial conduct.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
AbbVie’s Tavapadon Reduces Motor Impairments in Phase III Parkinson’s Trial
XTalks
DECEMBER 11, 2024
AbbVie has announced encouraging topline results from its Phase III TEMPO-2 clinical trial, evaluating tavapadon as a monotherapy for early Parkinsons disease. The trial met its primary and key secondary endpoints, demonstrating significant improvements in motor and daily living functions. These findings underscore tavapadons potential as a first-in-class treatment option, addressing unmet needs with strong efficacy and manageable side effects.
Trade & Channel Strategies 2024: Protecting the Pharma Supply Chain
Pharmaceutical Commerce
DECEMBER 11, 2024
The seminar focuses on US supply chain resiliency, while remaining compliant and preserving patient access.
How to Achieve CDMO Operational Excellence
Drug Patent Watch
DECEMBER 11, 2024
Achieving operational excellence in a Contract Development and Manufacturing Organization (CDMO) is crucial to ensure the quality and consistency of products and services. This can be achieved by implementing robust controls, optimizing workflows, and fostering a culture of continuous improvement. Here are some key strategies to achieve operational excellence in a CDMO: Implementing Robust Controls Compliance with Regulatory Guidelines : Ensure compliance with strict regulatory standards set by
Trade & Channel Strategies 2024: Patient-Centric 3.0 — How Direct-to-Patient is the New Commercialization Model
Pharmaceutical Commerce
DECEMBER 11, 2024
Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
CDMO Selection: The Ultimate Checklist
Drug Patent Watch
DECEMBER 11, 2024
The biopharmaceutical industry has witnessed a significant surge in the number of therapeutic molecules in development, leading to a corresponding increase in the number of contract development and manufacturing organizations (CDMOs). This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects.
Trade & Channel Strategies 2024: Navigating Pharma and Its Distribution Models
Pharmaceutical Commerce
DECEMBER 11, 2024
A case study explores a way to potentially transform commercial organizations, while driving revenue growth.
Innovating Cell-Based Solutions for Type 1 Diabetes ft. Jonathan Rigby, CEO, Sernova
XTalks
DECEMBER 11, 2024
In this episode, Ayesha spoke with Jonathan Rigby, MBA, CEO of Sernova , a Canadian biotech company developing innovative cell therapy-based approaches for the management of type 1 diabetes. The companys lead innovation is an implantable bio-hybrid organ pouch, which is currently in an ongoing Phase I/II clinical trial. An estimated 537 million people are currently living with diabetes globally and this number is projected to reach 643 million by 2030, making it a pressing health issue in need o
Pharma Pulse 12/11/24: Building and Maintaining Relationships with High-Profile Clients, Nearly Half of Adults With Epilepsy Use CBD Products & more
Pharmaceutical Commerce
DECEMBER 11, 2024
The latest news for pharma industry insiders.
Let's personalize your content